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Atrial ﬁbrillation (AF) is the most common sustained arrhythmia and an important source for mortality and morbidity on a population level.
Despite the clear association between AF and death, stroke, and other cardiovascular events, there is no evidence that rhythm control treat-
ment improves outcome in AF patients. The poor outcome of rhythm control relates to the severity of the atrial substrate for AF not only
due to the underlying atrial remodelling process but also due to the poor efﬁcacy and adverse events of the currently available ion-channel
antiarrhythmic drugs and ablation techniques. Data suggest, however, an association between sinus rhythm maintenance and improved sur-
vival. Hypothetically, sinus rhythm may also lead to a lower risk of stroke and heart failure. The presence of AF, thus, seems one of the
modiﬁable factors associated with death and cardiovascular morbidity in AF patients. Patients with a short history of AF and the underlying
heart disease have not been studied before. It is fair to assume that abolishment of AF in these patients is more successful and possibly also
safer, which could translate into a prognostic beneﬁt of early rhythm control therapy. Several trials are now investigating whether aggressive
early rhythm control therapy can reduce cardiovascular morbidity and mortality and increase maintenance of sinus rhythm. In the present
paper we describe the background of these studies and provide some information on their design.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction—Scope of the
problem
Atrial ﬁbrillation (AF) is the most common sustained arrhythmia
and an important source of mortality and morbidity on a popu-
lation level. Atrial ﬁbrillation is found in 1–2% of the general popu-
lation. More than 6 million people in Europe are affected and this is
expected to double during the next 30–50 years.
1–3 The esti-
mated lifetime risk of developing AF is one in four for the popu-
lation having reached the age of 55.
4 Atrial ﬁbrillation is not a
benign disease. It is associated with a doubled risk on death, a ﬁve-
fold increased risk of stroke, increased risk of heart failure and hos-
pitalization, a reduced exercise capacity and left ventricular func-
tion, and an impaired quality of life which may be worse in
women than in men.
5 Despite the clear association between AF
and death, stroke, and other cardiovascular events, there is no evi-
dence that rhythm control treatment improves outcome in AF
patients. All published studies have shown that rate control is
not inferior to rhythm control for the prevention of mortality
and morbidity (Tables 1 and 2).
6–12 This disappointing outcome
may relate to the low long-term maintenance rate of sinus
rhythm in the rhythm control groups of these studies, being 63%
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Table 1 Characteristics of rhythm control and rate control trials in patients with atrial ﬁbrillation (adapted from Camm et al. with permission)
1
Patients reaching primary endpoint (n)
Trial Patients
(n)
Mean
age
(years)
Mean length
of follow-up
(years)
Inclusion criteria Primary endpoint Rate control Rhythm control P
PIAF
8 252 61.0 1.0 Persistent AF (7–360 days) Symptomatic improvement 76/125 (60.8%) 70/127 (55.1%) 0.32
AFFIRM
6 4060 69.7 3.5 Paroxysmal AF or persistent AF, age 65
years or older, or risk of stroke or
death
All-cause mortality 310/2027 (25.9%) 356/2033 (26.7%) 0.08
RACE
7 522 68.0 2.3 Persistent AFor ﬂutter for ,1 yearand
1 to 2 cardioversions .2 years and
oral anticoagulation
Composite: cardiovascular death, CHF, severe
bleeding, PM implantation, thromboembolic events,
severe adverse effects of antiarrhythmic drugs
44/256 (17.2%) 60/266 (22.6%) 0.11
STAF
9 200 66.0 1.6 Persistent AF (.4 weeks and
,2years), left atrial size .45 mm,
CHF NYHA II–IV, LVEF ,45%
Composite: overall mortality, cerebrovascular
complications, CPR, embolic events
10/100 (10.0%) 9/100 (9.0%) 0.99
HOT CAFE ´10 205 60.8 1.7 First clinically overt persistent AF (≥7
and ,2 years), 50–75-year old
Composite: death, thromboembolic events;
intracranial/ major haemorrhage
1/101 (1.0%) 4/104 (3.9%) .0.71
AF-CHF
11 1376 66 3.1 LVEF≤35%, symptoms of CHF, history
of AF (≥6 h or ECV ,last
6 months)
Cardiovascular death 175/1376 (25%) 182/1376 (27%) 0.59
AF, atrial ﬁbrillation; AFFIRM, atrial ﬁbrillation follow-up investigation of rhythm management; CHF,congestive heart failure;CPR, cardiopulmonary resuscitation; ECV, electrical cardioversion; HOTCAFE, how to treatchronic atrial ﬁbrillation;
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PIAF, pharmacological intervention in atrial ﬁbrillation; PM, pacemaker; RACE, rate control versus electrical cardioversion for persistent atrial ﬁbrillation; STAF,
strategies of treatment of atrial ﬁbrillation.
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8after 5 years in the Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) trial and 39% after 2.3 years of
follow-up in the Rate Control versus Electrical Cardioversion
(RACE) trial. Also the Atrial Fibrillation and Congestive Heart
Failure trial (AF-CHF) observed no difference in cardiovascular
mortality (primary outcome) between patients with a left ventricu-
lar ejection fraction (LVEF) ≤35%, symptoms of congestive heart
failure and a history of AF randomized to rate or rhythm
control, nor in the secondary outcomes including death from
any cause and worsening of heart failure.
11 In addition, a
post-hoc time-dependent analysis did not show that sinus
rhythm was associated with improved outcome.
13 The negative
outcome of rhythm control therapy may also be a consequence
of ‘positive patient selection’. The enrolled patients were selected
by not having severe AF-related symptoms and having survived a
phase of AF-related complications. Furthermore, according to
the guidelines used when the rate vs. rhythm control studies
were performed, anticoagulant therapy was often withdrawn
from patients in the rhythm control arms based on the assumption
that sinus rhythm was present, resulting in a potentially avoidable
excess risk of ischaemic stroke.
5,14–16 On the other hand, it
should be noted that during rate control therapy morbidity and
mortality are still signiﬁcant. Even with oral anticoagulation the
residual stroke or systemic embolism rate in patients with AF
remains relatively high, ranging between 1.1 and 2.4%, depending
on the presence of risk factors.
17–20 Although recent studies
showed a trend towards reduction of events including stroke
(Figure 1),
7,20 further improvement of therapy to reduce
AF-associated events clearly is warranted.
Interestingly, a subgroup analysis of the AFFIRM trial demon-
strated an association between sinus rhythm maintenance and
improved survival.
14 This, together with the results of the recently
published ATHENA trial, supports the idea that the presence of AF
is one of the modiﬁable factors associated with death and cardio-
vascular morbidity in AF patients.
21 Apart from the beneﬁcial effect
of dronedarone on a composite endpoint, predominantly driven by
cardiovascular hospitalizations in the ATHENA trial, there are no
other controlled data that show a beneﬁt of rhythm control
therapy beyond improved quality of life.
22,23 Hence, current guide-
lines for the treatment of AF base the decision to add rhythm
control therapy to the management of AF on individual factors
interpreted by the physician and the patient. These factors
include the severity of complaints and how these will affect the
individual patients, and the severity of AF, i.e. how successful
rhythm control is expected to be.
1,24 Further elucidation of the
mechanisms and signals involved in the process of sustaining AF
might ultimately improve therapeutic strategies and outcome of
rhythm control therapy both for maintenance of sinus rhythm
and for prevention of morbidity and mortality.
...............................................................................................................................................................................
Table 2 Comparison of adverse outcomes in rhythm control and rate control trials in patients with atrial ﬁbrillation
(adapted from Camm et al. with permission)
1
Trial Deaths of all causes
(in rate/rhythm)
Deaths from
cardiovascular causes
Deaths from
non-cardiovascular causes
Stroke Thromboembolic
events
Bleeding
PIAF
8 4 1/1 1
a ND ND ND
AFFIRM
6 666 (310/356) 167/164 113/165 77/80 ND 107/96
RACE
7 36 18/18 ND ND 14/21 12/9
STAF
9 12 (8/4) 8/3 0/1 1/5 ND 8/11
HOT
CAFE ´10
4 (1/3) 0/2 1/1 0/3 ND 5/8
AF-CHF
11 228/217 175/182 53/35 11/9 ND ND
AF, atrial ﬁbrillation; AFFIRM, atrial ﬁbrillation follow-up investigation of rhythm management; HOT CAFE, how to treat chronic atrial ﬁbrillation; ND, not determined; PIAF,
pharmacological intervention in atrial ﬁbrillation; RACE, rate control versus electrical cardioversion for persistent atrial ﬁbrillation; and STAF, strategies of treatment of atrial
ﬁbrillation.
aTotal number of patients not reported.
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Figure 1 Yearly cardiovascular morbidity and mortality rate in
the Rate Control Versus Electrical Cardioversion (RACE) I study
(published in 2002) and the RAte Control Efﬁcacy in permanent
atrial ﬁbrillation (RACE) II study (published in 2010).
7,20
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control therapy
The causes underlying AF are multifactorial. Age, hypertension,
congestive heart failure, valve disease, and diabetes are all well-
known risk factors for the development of AF.
25–28 Less well-
known risk factors include, among others, endurance training,
obesity, sleep apnoea syndrome, and chronic obstructive pulmon-
ary disease.
1,29 These risk factors together with an altered metab-
olism, autonomic changes, and genetic and environmental factors
cause marked changes in the molecular function and structure of
the atria, which is called structural remodelling. The induced mol-
ecular and structural changes in the atria include cellular calcium
overload, activation of the renin2angiotensin2aldosterone
system, inﬂammation, oxidative stress, enlarged atria, hypertrophy,
ﬁbrosis, dedifferentiation, apoptosis, myolysis, and amyloidosis
(Figure 2).
30,31 Structural remodelling ultimately creates a substrate
for AF due to electrical dissociation between muscle bundles and
local conduction heterogeneities facilitating the initiation and per-
petuation of AF. Once AF develops, it causes marked changes in
atrial electrophysiology (‘electrical remodelling’) and further
deteriorates the structural remodelling process.
32–35 The ﬁrst
manifestation of AF usually occurs after years of atrial remodel-
ling.
35–37 Thus, atrial remodelling in patients with AF is caused
by both the associated diseases and AF itself and may contribute
to AF-related complications. Ultimately, due to ongoing remodel-
ling, patients progress to permanent AF.
38,39
The remodelling changes may still be reversible during early
phases of the arrhythmia, probably even more if the duration of
the underlying disease also is not too long,
40,41 but may provoke
relevant and permanent atrial damage during later stages of AF
and associated diseases. This may explain the disappointing
outcome of rhythm control therapy in prior studies, both for
the prevention of recurrent AF and for cardiovascular morbidity
and mortality. Most trials included patients in whom the extent
of remodelling was severe and even irreversible due to a long
history of both AF and the underlying heart disease. Since the
underlying disease is also a major contributor to the remodelling
process, in some patients a ﬁrst episode of AF may already be
untreatable, even with aggressive therapy, due to the presence of
substantial structural changes.
35,42 In patients with a shorter
history of both AF and the underlying disease, the remodelling pro-
cesses are assumingly less advanced, which may provide more
opportunities for rhythm control strategies to be effective.
30,34,43
By successfully eliminating AF the remodelling process may
become less progressive, reducing the extent of ﬁbrosis, inﬂam-
mation, atrial hypertrophy, and other adaptation processes.
Hypothetically, this may also lower the risk of complications
associated with AF, like stroke and heart failure.
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Figure 2 Flow chart showing the series of events caused by stretch. Hypothetical scheme of stretch induced by hypertension, heart failure
and possibly extreme endurance exercise leading to calcium overload, activation of the renin2angiotensin2aldosterone system and release of
different factors, resulting in structural remodelling and ﬁnally in atrial ﬁbrillation (Adapted with permission from De Jong et al.).
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relatively effective rhythm
control therapies: ablation,
new antiarrhythmic drugs,
and upstream therapy
The poor outcome of rhythm control relates to the severity of the
atrial substrate for AF not only due to the underlying atrial remo-
delling process but also due to the poor efﬁcacy and adverse
events of the currently available ion-channel antiarrhythmic drugs
and ablation techniques.
44–55
While catheter ablation was not incorporated into the rate vs.
rhythm control trials, today it is increasingly performed in patients
with symptomatic AF. Pulmonary vein isolation is the cornerstone
of all ablation procedures. In most centres this is performed with
one long, encircling lesion around the right and another lesion
around the left pulmonary veins. Several prospective randomized
trials comparing ablation vs. antiarrhythmic drugs to maintain
sinus rhythm consistently show that ablation therapy is signiﬁcantly
more effective in maintaining sinus rhythm compared with anti-
arrhythmic drugs with an overall risk reduction of AF recurrence
by 65 to 70% at 1-year follow-up, keeping in mind that most of
these trials have shortcomings in detecting recurrent AF.
1,51–55
A recent meta-analysis showed a single-procedure success rate
of ablation off antiarrhythmic drugs of 57%, a multiple procedure
success rate off antiarrhythmic drugs of 71%, and a multiple pro-
cedure success rate on antiarrhythmic drugs of 77%. In compari-
son, the success rate for antiarrhythmic drug therapy was 52%.
56
Whether these short-term success rates may be extrapolated to
long-term success is yet unclear. Data on long-term outcome for
catheter ablation for AF are scarce. Tzou et al.
57 recently reported
on 123 consecutive patients with paroxysmal or persistent AF who
underwent pulmonary vein isolation and were free from AF and
without antiarrhythmic drugs 1 year after ablation. Long-term abla-
tion success, deﬁned as freedom from AF off antiarrhythmic drugs
after a single-ablation procedure, was 85% at 3 years and 71% at
5 years, with an  7% per year late recurrence rate after the
ﬁrst year. Predictors for late recurrences were the known risk
factors for AF (progression),
39 including higher age, hypertension,
larger left atrial size, as well as more AF triggers being present
during the electrophysiological procedure, and patients who
present with persistent AF. The Bordeaux group showed compar-
able late success rates.
58 Arrhythmia-free survival following the last
catheter ablation procedure was, in 100 patients undergoing abla-
tion in 2001–2002 in their experienced hands, 87, 81, and 63% at
1, 2, and 5 years, respectively. Valvular heart disease and non-
ischaemic dilated cardiomyopathy independently predicted recur-
rences. Thus, although most recurrences transpire over the ﬁrst
6–12 months, a slow but steady decline in arrhythmia-free survival
is noted thereafter, even after three or more years of apparent
arrhythmia control. Nevertheless, catheter ablation for AF
appears to be more effective in maintaining sinus rhythm compared
with antiarrhythmic drug therapy. It might be even more effective
when considering the fact that most ablation studies included
patients with a relatively long history of AF and the associated
disease who had failed serial antiarrhythmic drug testing. Thus,
success might be further improved by a better selection of patients
and more efﬁcacious and safe ablation techniques. The highest efﬁ-
cacy of catheter ablation is observed in younger patients with less
severe atrial remodelling.
57,59 The procedure is relatively safe with
a 5% overall complication rate.
56,60 Feared complications include
tamponade, stroke, pulmonary vein stenosis, permanent diaphrag-
matic paralysis, and oesophageal ﬁstula.
60 Repeat procedures,
however, are necessary in up to 40% of all patients. Only one
small study investigated catheter ablation and antiarrhythmic
drugs as ﬁrst-line therapy in patients with a duration of AF of
.8 months.
51 Duration of the associated disease was not
reported. At 1 year of follow-up 80% of patients who had under-
gone catheter ablation were free of AF. It is, however, unknown
yet as to whether an early ablation therapy and a further optimiz-
ation of ablation procedures could further improve success rate
and reduce complications associated with the ablation procedure,
and, in turn, may improve cardiovascular outcomes like mortality,
cardiovascular hospitalizations, worsening of heart failure, and
stroke.
Safer and more effective antiarrhythmic drugs may also improve
the success rate of a rhythm control strategy. Ion channel-blocking
antiarrhythmic drugs may counteract the electrical remodelling,
but leave other mechanisms like the structural remodelling
process untouched. In addition, these drugs all carry a relatively
high risk of adverse events including life-threatening arrhythmias
like torsades de pointes. For that reason the recommended
dosages often cannot be instituted, which might reduce success
rates. A number of new class III and atrial selective drugs have
been developed.
61 However, most of these drugs were abandoned
before approval due to the risk of proarrhythmia. Dronedarone, a
novel benzofuran derivative structurally related to amiodarone, has
recently been approved and may improve the outcome of rhythm
control therapy. It has a beneﬁcial safety proﬁle both in patients
without structural heart disease and in those with stable
mild-to-moderate heart disease and seems to carry a very low
risk for proarrhythmia.
21,62 However, it is contraindicated in
patients with impaired left ventricular function [New York Heart
Association (NYHA) class III/IV] and haemodynamic instability
because of the data of the ANDROMEDA study.
63 This study
investigated the effect of dronedarone on the risk of hospitalization
for progressive heart failure in a placebo-controlled study in
patients with NYHA class III or IV congestive heart failure, and a
LVEF ,35%. After 2 months this trial was terminated because of
a higher mortality rate in the dronedarone treatment group due
to progressive heart failure. Similar to sotalol, propafenone, and
ﬂecainide, dronedarone is less effective to maintain sinus rhythm
compared with amiodarone,
62,64 but its efﬁcacy has not been
tested in patients with early AF. Of signiﬁcance are the beneﬁcial
results of dronedarone on improvement of outcome. Data from
the recently published ATHENA trial on outcome in patients
with AF showed a reduction of the primary composite outcome
driven by cardiovascular hospitalizations (hazard ratio 0.74, 95%
conﬁdence interval 0.69–0.84, P , 0.0001).
21 Additionally, a
post-hoc analysis of ATHENA showed a reduction of stroke.
65
Comparable beneﬁcial outcome effects have been demonstrated
for amiodarone,
50 but this beneﬁcial effect is counteracted by a
Early rhythm control for atrial ﬁbrillation 1521high rate of non-cardiac adverse events.
50,66 Adverse effects associ-
ated with dronedarone have also been reported but seem to be
less harmful.
21,62,64 Thyroid, ocular, or pulmonary side effects in
these studies were not signiﬁcantly different from placebo-treated
patients. Similar to amiodarone, however, dronedarone is associ-
ated with an increase in serum creatinine, which are assumed to
be the result of inhibition of tubular secretion, independent of
renal function.
67 This is particularly the case in patients who use
other drugs increasing serum creatinine.
62
Substrate-oriented antiarrhythmic drug therapy that modiﬁes
the structural atrial remodelling process may also improve
the outcome of rhythm control. ‘Upstream therapy’ refers to the
use of non-ion channel antiarrhythmic drugs that modify the
atrial substrate to prevent the occurrence of new onset AF or
recurrence of the arrhythmia. It includes treatment with renin2
angiotensin2aldosterone system (RAAS) blockers [angiotensin-
converting enzyme inhibitors (ACE-inhibitor), angiotensin receptor
blockers, aldosterone receptor antagonists], statins, and omega-3
polyunsaturated fatty acids. The RAAS blockers may prevent or
reduce atrial structural remodelling especially by decreasing ﬁbro-
sis. In addition, these drugs improve haemodynamics by lowering of
blood pressure and reduction of left ventricular and atrial wall
stress, which also may have beneﬁcial effects on the remodelling
process. Statins, known for their lipid-lowering capacities, have a
variety of pleiotropic properties including attenuation of inﬂam-
mation through anti-atherogenic and antioxidant actions. Results
of upstream therapy for the prevention of AF in animal exper-
iments, hypothesis-generating small clinical studies, and retrospec-
tive analyses in selected patient categories have been encouraging.
Larger prospective randomized trials, however, did fail to show any
protective beneﬁt against AF in patients with and without struc-
tural heart disease,
40,68–70 while patients with known left ventricu-
lar dysfunction
71 or with diabetes mellitus and left ventricular
hypertrophy
36 experience less new onset AF on ACE-inhibitor
or sartans compared with placebo or beta-blockers. This suggests
that inhibition of the renin2angiotensin system may be helpful to
prevent AF in patients whose atria are exposed to marked volume
or pressure overload by systolic or diastolic dysfunction. The ran-
domized trials so far included patients in whom the extent of
remodelling was severe and even irreversible due to a longer
history of AF and underlying heart disease. In patients with a
shorter history of AF and the underlying disease, remodelling pro-
cesses are assumingly less advanced, providing greater opportunity
for upstream therapies to be effective.
The need for staged therapy
Atrial ﬁbrillation is responsible for a ﬁve-fold increase in the risk of
ischaemic stroke. Therefore, oral anticoagulation therapy is the
cornerstone for the treatment of AF patients with an increased
risk of thromboembolic complications.
72 Such treatment is
needed independently from the therapeutical strategy decided,
rate, or rhythm control. But even with oral anticoagulation the
residual stroke or systemic embolism rate in patients with AF
remains relatively high.
17–20 The presence of AF seems one of
the modiﬁable factors associated with death and cardiovascular
morbidity in AF patients.
We can therefore hypothesize that if effective and safe methods
for maintaining sinus rhythm with fewer adverse effects become
available rhythm control therapy may become the ﬁrst choice
therapy in more patients. A promising strategy might be catheter
ablation combined with safe antiarrhythmic drugs and substrate-
oriented antiarrhythmic drugs with beneﬁcial effects on outcome
parameters. Catheter ablation is nowadays an effective therapy
but only retrospective evidence supports the notion that catheter
ablation may result in reduced mortality.
73 Therefore, prospective
randomized trials that include catheter ablation and new anti-
arrhythmic drugs for rhythm control are needed to reafﬁrm the
concept that sinus rhythm maintenance may improve outcome.
These trials preferably should be performed in patients with a
short history of AF and the underlying disease, i.e. in patients
with less severe remodelled atria.
Perspective: slowing down the
progression of atrial ﬁbrillation to
prevent atrial ﬁbrillation-related
complications
Patients with a short history of AF and the underlying heart disease
have not been studied before. It is fair to assume that the abolish-
ment of AF in these patients is more successful and possibly also
safer, which could translate into a prognostic beneﬁt of early
rhythm control therapy. Several trials are now investigating
whether aggressive early rhythm control therapy can reduce cardi-
ovascular morbidity and mortality and increase the maintenance of
sinus rhythm. The Radiofrequency Ablation versus Antiarrhythmic
drugs for Atrial Fibrillation Treatment (RAAFT) study (Clinical
Trials.gov number NCT00393054)
74 randomized 130 patients
naı ¨ve to antiarrhythmic drugs to either atrial ablation or anti-
arrhythmic drugs as ﬁrst-line treatment of symptomatic AF. Their
primary endpoint is time to ﬁrst recurrence of electrocardiographi-
cally documented symptomatic AF lasting .30 s. A second trial,
the Catheter ABlation versus ANti-arrhythmic drug therapy for
Atrial ﬁbrillation trial (CABANA, Clinical Trials.gov number
NCT00911508) currently randomizes patients to left atrial endo-
cardial catheter ablation or current state-of-the-art therapy with
either rate or rhythm control drugs. This study aims to include
3000 patients with risk factors for stroke. The hypothesis is that
eliminating AF will be superior for reducing total mortality. The
Routine versus Aggressive upstream rhythm Control for the pre-
vention of Early atrial ﬁbrillation in heart failure study (RACE 3,
NCT00877643) includes patients with early AF (total AF history
,2 years, total persistent AF duration ,6 months, and ≤1 pre-
vious electrical cardioversion), and mild-to-moderate early heart
failure (total heart failure history ,1 year). Patients are random-
ized to aggressive upstream therapy with structured physical
activity or routine rhythm control as described in the 2010 AF
guidelines.
1 The primary endpoint of the study is sinus rhythm
after 1 year of follow-up, deﬁned as sinus rhythm during ≥6/7th
of assessable time of continuous 7 days Holter monitoring
during the last week of the study.
1,75 Finally, the Early treatment
of Atrial ﬁbrillation for Stroke prevention Trial (EAST, ISRCTN-Nr:
I.C. Van Gelder et al. 152204708680) will soon start to include high-risk patients with short-
lasting AF (known history of AF ,1 year). This trial will randomize
3150 patients to early rhythm control therapy either by atrial cath-
eter ablation or antiarrhythmic drugs (preferably dronedarone, and
in case of a recurrence both modalities), or usual care as described
in the 2010 AF guidelines.
1 The primary outcome is cardiovascular
mortality, stroke, transient ischaemic attack, and hospitalization
due to worsening of heart failure or acute coronary syndrome.
All authors will participate in the planned EAST trial. The above-
mentioned studies will give us new insight into whether slowing
down the progression of AF may prevent AF-related
complications.
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